Safety, Tolerability and Efficacy Study of PP1420 in HV

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-31

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obesity is a growing pandemic which affects 1 in 4 adults in the UK, and shortens life by increasing cardiovascular disease, diabetes and cancer. Current treatments for obesity have either poor efficacy or significant side effects. Pancreatic polypeptide (PP) is a promising new drug target as it produces powerful appetite suppression which, following a 90-minute infusion continues to act for 24 h in man. We have developed a new long lasting high potency analogue of PP, PP1420. This is delivered as a once-a-day subcutaneous injection via a painless fine-gauge needle.

In a first-time-in-man Phase 1a trial, that PP 1420 proved safe, well tolerated, and had extended pharmacokinetics compared to PP itself.

We now plan to study the safety and PK of PP1420 up to 64mg. We will also assess:

1. Its efficacy in reducing food intake after a single dose in a Phase 1B study in healthy volunteers.
2. Its efficacy in reducing food intake and weight after multiple dosing in a Phase 1C study in healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects

NCT01052493

Obesity

COMPLETED PHASE1

Safety and Pharmacokinetic Study of Y242 in Adult Subjects

NCT01515319

Obesity

COMPLETED PHASE1

A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects

NCT01540864

Obesity Overweight

TERMINATED PHASE2

Safety and Tolerability of Liraglutide in Healthy Male Volunteers

NCT01507272

Diabetes Healthy

COMPLETED PHASE1

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

NCT00396448

Obesity

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

More than 25% of people in the UK are obese. People with obesity have a shorter life expectancy, and have a higher risk of having heart attacks, strokes, high blood pressure, diabetes, and certain cancers.

At the moment, there is no treatment for obesity that is both effective and safe. Advising people to change their diet and to exercise more is frequently ineffective, and any loss in weight seen is usually temporary. There is only one medications licensed for the purpose of losing weight, but they are limited by side-effects. Finally, gastric bypass and similar surgeries are effective at reducing weight permanently, but can be risky and restricted only to very motivated people.

"Gut hormones" are natural chemicals made by the bowels when you eat. They work to reduce appetite and hunger when you eat, so that you will eat enough for your needs. We think that one of the reasons why gastric bypass surgery is so effective is because the surgery causes an increase in gut hormone secretion into the bloodstream, which suppresses appetite. One of these hormones is pancreatic polypeptide (PP), which is released into the bloodstream by cells in the pancreas after eating. When human PP is given to healthy volunteers as an injection, we see that they have a reduced appetite and food intake with no side-effects such as feeling sick or vomiting.

Human PP does not last long in the blood stream. In order to make it into a new, safe and effective drug for obesity, we have developed a new form of PP, which is very similar but not identical to human PP, that we expect will last longer in the blood. We call this PP 1420.

In testing, PP 1420 reduced food intake in animals, and was safe in them at much higher doses than those we plan to give in the current study.

PP1420 has previously been give to healthy volunteers in single doses up to 8mg without any serious problems. All doses were well tolerated.

This study will examine the safety and tolerability of PP 1420 when given at single doses of higher doses, up to 64 mg, and the safety, tolerability and efficacy of PP 1420 when given in multiple doses for up to 28 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.

Visit: 2 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously.

Visit 3 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.

Group Type EXPERIMENTAL

PP1420

Intervention Type DRUG

Single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.

Placebo

Intervention Type DRUG

0.9% (w/v) saline single-dose, administered subcutaneously

Arm 2

Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.

Visit: 2 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.

Visit 3 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously.

Group Type EXPERIMENTAL

PP1420

Intervention Type DRUG

Single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.

Placebo

Intervention Type DRUG

0.9% (w/v) saline single-dose, administered subcutaneously

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PP1420

Single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.

Intervention Type DRUG

Placebo

0.9% (w/v) saline single-dose, administered subcutaneously

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pancreatic Polypeptide 1420

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male as determined by a responsible physician, based on a medical evaluation including history, physical examination, vital signs, laboratory tests and 12-lead ECG.
2. Between 18 and 50 years of age, inclusive, at the time of signing and dating the informed consent form.
3. Body weight 70 kg and body mass index (BMI) within the range 25 - 35 kg/m2 (inclusive).
4. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
5. Willing and able to comply with the protocol for the duration of the study.

Exclusion Criteria

1. As a result of the medical interview, physical examination, or screening investigations, the Investigator considers the subject unsuitable for the study.
2. The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
3. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
4. A positive test for human immunodeficiency virus (HIV) antibody.
5. History of migraine.
6. History or evidence of abnormal eating behaviour, as observed through the Dutch Eating Behaviour (DEBQ) and SCOFF questionnaires.
7. History of excessive alcohol consumption within 6 months of the study defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units. One unit is equivalent to 8 g of alcohol, a half-pint (approximately 240 mL) of beer or 1 measure (25 mL) of spirits or 1 glass (125 mL) of wine.
8. Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
9. Has QTc at screening \>450 msec.
10. Systolic blood pressure outside the range 85 - 160 mmHg, diastolic blood pressure outside the range 45 - 100 mmHg, and/or heart rate outside the range 40 - 110 bpm.
11. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the dosing day in the current study: 90 days, five half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
12. Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
13. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days or five half-lives (whichever is longer) prior to the dose of study medication, which, in the opinion of the Investigator, may interfere with the study procedures or compromise subject safety.
14. History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator, contraindicates their participation.
15. Where participation in the study would result in donation of blood in excess of 500 mL within 3 months before or after the study.
16. Unwilling to abstain from:

* Consumption of caffeine- or xanthine- containing products for 24 hours prior to dosing until the post-dose assessment at each treatment level.
* Use of illicit drugs.
* Alcohol for 48 hours prior to dosing until final post-dose assessment at each treatment level.
* Smoking or otherwise consuming tobacco for 24 hours prior to dosing until the post-dose assessment at each treatment level.
17. Unwilling or unable to use a condom during sexual activity from first dose until the end of the study.
18. Vegans and subjects with milk or wheat intolerance or allergy as reported by the subject.
19. Unwillingness or inability to follow the procedures outlined in the protocol.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes